CLINICAL STUDY: SYSTEMIC AND PULMONARY HYPERTENSION
Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
Nazzareno Galiè, MD*,*,
Alan L. Hinderliter, MD ,
Adam Torbicki, MD ,
Thierry Fourme, MD ,
Gerald Simonneau, MD ,
Tomas Pulido, MD||,
Nilda Espinola-Zavaleta, MD||,
Guido Rocchi, MD*,
Alessandra Manes, MD*,
Robert Frantz, MD¶,
Marcin Kurzyna, MD ,
Sherif F. Nagueh, MD#,
Robyn Barst, MD**,
Richard Channick, MD ,
Karl Dujardin, MD ,
Andrew Kronenberg, MD ,
Isabelle Leconte, PhD ,
Maurizio Rainisio, PhD and
Lewis Rubin, MD
* Institute of Cardiology, University of Bologna, Italy
Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
Department of Chest Medicine, Institute of Tuberculosis and Lung Disease, Warsaw, Poland
Division of Pulmonary and Critical Care Medicine, University of Paris-Sud, Paris, France
|| Instituto Nacional de Cardiologia, Mexico City, Mexico
¶ Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
# Baylor College of Medicine and the Methodist Hospital, Houston, Texas, USA
** Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA
 Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California, USA
 Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium
 Actelion Ltd., Allschwil, Switzerland
Manuscript received August 11, 2002;
revised manuscript received December 20, 2002,
accepted January 2, 2003.
* Reprint requests and correspondence: Dr. Nazzareno Galiè, Istituto di Cardiologia, Università di Bologna, via Massarenti, 9, 40138-Bologna, Italy. n.galie{at}bo.nettuno.it
OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH).
BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH.
METHODS: Patients had primary pulmonary hypertension (84%) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment.
RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardiographic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.4 l/min/m2 (p = 0.007), LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = 0.12 (p = 0.047), RV end-systolic area = 2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = 0.64 (p = 0.007), Doppler RV index = 0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17% (p = 0.05).
CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.
|
Abbreviations and Acronyms
| | BREATHE-1 | | Bosentan Randomized trial of Endothelin Antagonist Therapy for pulmonary hypertension | | LV | | left ventricle/ventricular | | PAH | | pulmonary arterial hypertension | | PPH | | primary pulmonary hypertension | | RV | | right ventricle/ventricular | | WHO | | World Health Organization |
|
This article has been cited by other articles:

|
 |

|
 |
 
L. P. Badano, C. Ginghina, J. Easaw, D. Muraru, M. T. Grillo, P. Lancellotti, B. Pinamonti, G. Coghlan, M. P. Marra, B. A. Popescu, et al.
Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects
Eur J Echocardiogr,
October 7, 2009;
(2009)
jep152v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J-L. Vachiery and G. Coghlan
Screening for pulmonary arterial hypertension in systemic sclerosis
Eur. Respir. Rev.,
September 1, 2009;
18(113):
162 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Eur. Respir. J.,
July 1, 2009;
34(1):
231 - 242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al.
Diagnosis and assessment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S55 - S66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie
Updated evidence-based treatment algorithm in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S78 - S84.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S97 - 107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G.J. Duffels, M. Hardziyenka, S. Surie, R. H.A.C.M de Bruin-Bon, E. S. Hoendermis, A. P.J. van Dijk, B. J. Bouma, H. L. Tan, R. M.F. Berger, P. Bresser, et al.
Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension
Eur J Echocardiogr,
May 1, 2009;
10(3):
433 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O Kowal-Bielecka, R Landewe, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C Denton, D Farge, K Fligelstone, et al.
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
Ann Rheum Dis,
May 1, 2009;
68(5):
620 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galiè and A. Manes
CHAPTER 24 Pulmonary Hypertension
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, and M. Tamm
A randomised, controlled trial of bosentan in severe COPD
Eur. Respir. J.,
September 1, 2008;
32(3):
619 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut
Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Proceedings of the ATS,
July 15, 2008;
5(5):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S G Haworth
The management of pulmonary hypertension in children
Arch. Dis. Child.,
July 1, 2008;
93(7):
620 - 625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Avouac, J Wipff, A Kahan, and Y Allanore
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
Ann Rheum Dis,
June 1, 2008;
67(6):
808 - 814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.G. Coghlan and J. Davar
How should we assess right ventricular function in 2008?
Eur. Heart J. Suppl.,
December 1, 2007;
9(suppl_H):
H22 - H28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. M. Lang
Management of acute and chronic RV dysfunction
Eur. Heart J. Suppl.,
December 1, 2007;
9(suppl_H):
H61 - H67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie, A. Manes, M. Palazzini, L. Negro, S. Romanazzi, and A. Branzi
Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension
Eur. Heart J. Suppl.,
December 1, 2007;
9(suppl_H):
H68 - H74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Huez, F. Roufosse, J-L. Vachiery, A. Pavelescu, G. Derumeaux, J-C. Wautrecht, E. Cogan, and R. Naeije
Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?
Eur. Respir. J.,
November 1, 2007;
30(5):
928 - 936.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Gaine and J. Behr
Confidence from experience: dual endothelin receptor antagonism in PAH
Eur. Respir. Rev.,
August 1, 2007;
16(102):
1 - 2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Torbicki
Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction
Eur. Heart J.,
May 5, 2007;
(2007)
ehm074v1.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. van Wolferen, J. T. Marcus, A. Boonstra, K. M.J. Marques, J. G.F. Bronzwaer, M. D. Spreeuwenberg, P. E. Postmus, and A. Vonk-Noordegraaf
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension
Eur. Heart J.,
May 2, 2007;
28(10):
1250 - 1257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study
Heart,
March 1, 2007;
93(3):
350 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Ruan and S. F. Nagueh
Clinical Application of Tissue Doppler Imaging in Patients With Idiopathic Pulmonary Hypertension
Chest,
February 1, 2007;
131(2):
395 - 401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Collins, B. Bastian, L. Quiqueree, C. Jones, R. Morgan, and G. Reeves
Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I)
Eur J Echocardiogr,
December 1, 2006;
7(6):
439 - 446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Forfia, M. R. Fisher, S. C. Mathai, T. Housten-Harris, A. R. Hemnes, B. A. Borlaug, E. Chamera, M. C. Corretti, H. C. Champion, T. P. Abraham, et al.
Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
November 1, 2006;
174(9):
1034 - 1041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Voelkel, R. A. Quaife, L. A. Leinwand, R. J. Barst, M. D. McGoon, D. R. Meldrum, J. Dupuis, C. S. Long, L. J. Rubin, F. W. Smart, et al.
Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure
Circulation,
October 24, 2006;
114(17):
1883 - 1891.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug.
Experimental Biology and Medicine,
June 1, 2006;
231(6):
653 - 695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Fijalkowska, M. Kurzyna, A. Torbicki, G. Szewczyk, M. Florczyk, P. Pruszczyk, and M. Szturmowicz
Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension
Chest,
May 1, 2006;
129(5):
1313 - 1321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
Heart,
November 1, 2005;
91(11):
1447 - 1452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Piazza and S. Z. Goldhaber
The Acutely Decompensated Right Ventricle: Pathways for Diagnosis and Management
Chest,
September 1, 2005;
128(3):
1836 - 1852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Am. J. Respir. Crit. Care Med.,
June 1, 2005;
171(11):
1292 - 1297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra
Pulmonary Arterial Hypertension: The Key Role of Echocardiography
Chest,
May 1, 2005;
127(5):
1836 - 1843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J.,
December 2, 2004;
25(24):
2243 - 2278.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Sitbon, V. Gressin, R. Speich, P. S. Macdonald, M. Opravil, D. A. Cooper, T. Fourme, M. Humbert, J.-F. Delfraissy, and G. Simonneau
Bosentan for the Treatment of Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
December 1, 2004;
170(11):
1212 - 1217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Humbert, O. Sitbon, and G. Simonneau
Treatment of Pulmonary Arterial Hypertension
N. Engl. J. Med.,
September 30, 2004;
351(14):
1425 - 1436.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Hachulla and J G Coghlan
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
Ann Rheum Dis,
September 1, 2004;
63(9):
1009 - 1014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki
End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
48S - 55S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Channick, O. Sitbon, R. J. Barst, A. Manes, and L. J. Rubin
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
62S - 67S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie, W. Seeger, R. Naeije, G. Simonneau, and L. J. Rubin
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
81S - 88S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.M. Kawut and H.I. Palevsky
New answers raise new questions in pulmonary arterial hypertension
Eur. Respir. J.,
June 1, 2004;
23(6):
799 - 801.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J.,
June 1, 2004;
23(6):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Wilkins
Selective or Nonselective Endothelin Receptor Blockade in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
February 15, 2004;
169(4):
433 - 434.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie, A. Manes, and A. Branzi
The endothelin system in pulmonary arterial hypertension
Cardiovasc Res,
February 1, 2004;
61(2):
227 - 237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mehta
Drug Therapy for Pulmonary Arterial Hypertension: What's on the Menu Today?
Chest,
December 1, 2003;
124(6):
2045 - 2049.
[Full Text]
[PDF]
|
 |
|
|